Search Press releases Keywords From To 22 Oct 2024 UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting Read More 14 Oct 2024 UCB receives U.S. FDA approval for 320 mg single-injection device presentations of BIMZELX[®] (bimekizumab-bkzx) Read More 11 Oct 2024 UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and MGFA Scientific Session Read More 10 Oct 2024 Transparency notification BlackRock, Inc. Read More 9 Oct 2024 Transparency notification BlackRock, Inc. Read More 3 Oct 2024 Transparency notification BlackRock, Inc. Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
